Scopolamine
Administration
- Type: Anticholinergics, Cycloplegic
- Dosage Forms:
- Routes of Administration: scopolamine- transdermal. Scopolamine hydrobromide- IV, oral, Ophthalmic
- Common Trade Names:
Adult Dosing
- 0.32-0.1mg IV/IM/SubQ
- 0.4-0.8mg PO
- 1-2 drops (0.25% ophthalmic solution) up to 4 times daily
- 1 transdermal patch q72h (each 1.5mg patch delivers 1mg scopolamine over 72h)
Pediatric Dosing
- Sedation:
- 6mo-3y: 0.1-0.15 mg IM/IV/subQ
- 3-6y: 0.2-0.3 mg IM/IV/subQ
- Vomiting: 6 mcg/kg subQ
- Transdermal patch not FDA-approved for children
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk is minimal
- Renal dosing: contraindicated in renal impairment
- Hepatic dosing: contraindicated in hepatic impairment
Contraindications
- Allergy to class/drug
- Glaucoma
- Chronic lung disease (repeated doses)
- Prostatic hypertrophy
- Pyloric obstruction
Adverse Reactions
Serious
- Tachyarrhythmia
- Hallucinations, confusion
- Glaucoma
- Systemic absorption of ophthalmic formulation
Common
- Dry skin, diminished sweating
- Xerostomia
- Amnesia, somnolence
- Mydriasis, blurred vision
- Local irritation
Pharmacology
- Half-life: 9.5h (transdermal)
- Metabolism:
- Excretion:
Mechanism of Action
- Belladonna alkaloid with anticholinergic (predominantly antimuscarinic) properties